DOSING & ADMINISTRATION

OXLUMO™ (lumasiran) is a subcutaneous injection administered by a healthcare professional1

OXLUMO is dosed based on actual body weight

Image
`


3 monthly starting doses aim to
reduce urinary oxalate (UOx)1

Image
'


Ongoing dosing beginning one month after the last
starting dose aims to sustain the reduction1

The dosing regimen of OXLUMO is based on actual body weight1

Select a weight range to see the recommended dosing regimen.

3 starting doses: 3 mg/kg administered monthly

3mg/kg dose

Start

3mg/kg dose

Month 1

3mg/kg dose

Month 2

Ongoing dosing: 3 mg/kg administered quarterly beginning one month after the last starting dose

3mg/kg dose

Month 3

No dose

Month 4

No dose

Month 5

3mg/kg dose

Month 6

Ongoing quarterly dosing continues past month 6

Download the Dosing Guide

3 starting doses: 6 mg/kg administered monthly

6mg/kg dose

Start

6mg/kg dose

Month 1

6mg/kg dose

Month 2

Ongoing dosing: 6 mg/kg administered quarterly beginning one month after the last starting dose

6mg/kg dose

Month 3

No dose

Month 4

No dose

Month 5

6mg/kg dose

Month 6

Ongoing quarterly dosing continues past month 6

Download the Dosing Guide

3 starting doses: 6 mg/kg administered monthly

6mg/kg dose

Start

6mg/kg dose

Month 1

6mg/kg dose

Month 2

Ongoing dosing: 3 mg/kg administered monthly beginning one month after the last starting dose

3mg/kg dose

Month 3

3mg/kg dose

Month 4

3mg/kg dose

Month 5

3mg/kg dose

Month 6

Ongoing monthly dosing continues past month 6

Download the Dosing Guide

What if my patient misses a dose?

If a dose is delayed or missed, administer OXLUMO as soon as possible and resume the prescribed regimen from the most recently administered dose.1

Image
`

Administered via subcutaneous injection by a healthcare professional1

  • Doses are typically administered in office
  • Some patients may qualify to receive the injection at home from a healthcare professional, depending on their insurance coverage
  • OXLUMO can cause injection site reactions. Symptoms included erythema, pain, pruritus, and swelling

See the full Prescribing Information for detailed steps on how to prepare and administer OXLUMO.

Show Me the Prescribing Information

Image

WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?

Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.

Let's Connect

Image
'

There’s more to learn about OXLUMO

When you sign up, we will keep you informed with updates and resources.

Sign Me Up

Image
Alnylam Assist® Logo

Access to OXLUMO starts here

We’re here to make the process of getting started simple for your patient.

Take Me to the Start Form

Reference: 1. OXLUMO (lumasiran) [Package Insert]. Cambridge, MA. Alnylam Pharmaceuticals, Inc.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common adverse reaction that occurred in patients treated with OXLUMO™ (lumasiran) was injection site reaction (38%). Symptoms included erythema, pain, pruritus, and swelling.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.